DERM
Journey Medical Corporation Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Journey Medical (DERM) Stock: Buy, Sell, or Hold?
$4.50
+0.08 (+1.81%)
▲
5d:
-4.86%
30d:
-20.77%
90d:
-32.33%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 12, 2026
TODAY
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (80%)
Quality Score
58/100
Position
OVERSOLD
30-Day Fair Range
$4.58 – $5.80
Position: OVERSOLD
Forward P/E & Valuation
10.0x
CHEAP
vs 15.3x historical avg
Wall Street Target
$13.75
+211.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.25 / $5.48
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: DERM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.49
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.89
23.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $4.50, which is considered oversold relative to its 30-day fair value range of $4.58 to $5.80. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.0) compared to its historical average (15.3). Remarkably, the market is currently pricing in an annual earnings decline of 13.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a downtrend. Immediate support is located at $4.25, while resistance sits at $5.47.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.75 (+211.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DERM is in a downtrend. Immediate support is located at $4.25, while resistance sits at $5.47.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.75 (+211.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.58 -
$5.80
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Trading Range & Key Levels
30-Day Trading Range
$4.58 -
$5.80
Current vs Trading Range
OVERSOLD
Support Level
$4.25
Resistance Level
$5.48
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 211.1% below Wall St target ($13.75)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Fundamental Context
Forward P/E (Next Year Est.)
9.99
Wall Street Target
$13.75
(+211.1%)
Revenue Growth (YoY)
23.3%
Profit Margin
-8.9%
Valuation Discount vs History
-13.3% cheaper
PE vs Historical
10.0 vs 15.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.3%
(market-implied from PE analysis)
1-Year Target
$3.98
(-10%)
2-Year Target
$3.58
(-19%)
3-Year Target
$3.22
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→15)
$4.94
(+12%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 15.3
Stabilization Target:
$6.77
(+53.2%)
PE Expansion Potential:
+53.2%
Share DERM Analysis
Share this live DERM analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (DERM)
Bearish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Bearish sentiment dominates $DERM on StockTwits with no new information from Yahoo Finance.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 2:43 PM ET
Data refreshes hourly during market hours. Next update: 3:43 PM
Data refreshes hourly during market hours. Next update: 3:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive DERM Research Pages
